Can Raynaud’s Affect the Heart?

Raynaud’s phenomenon is best known for turning fingers and toes white or blue in the cold, but the same kind of blood-vessel spasm can occur in the heart. The connection is strongest in people whose Raynaud’s is linked to an underlying autoimmune disease like systemic sclerosis, where a concept called “myocardial Raynaud’s” has been documented for decades. Even in primary Raynaud’s, though, researchers have found higher rates of chest pain, subtle shifts in how the heart’s nerves behave, and a possible link to cardiovascular mortality over the long term. The picture is more nuanced than a simple yes or no.

Chest Pain Is Surprisingly Common in Raynaud’s

One of the earliest clues that Raynaud’s might reach beyond the fingertips came from studies of chest pain. In a controlled study comparing people with primary Raynaud’s disease to matched controls, about half of the Raynaud’s group reported chest pains, compared with roughly one in six controls. The odds of having chest pain were more than four times higher in the Raynaud’s group, and the association was even stronger among those who also experienced migraines.¹ That migraine connection is telling: migraines also involve abnormal blood-vessel behavior, which suggests a body-wide tendency toward vasospasm rather than a problem limited to the hands.

Chest pain in someone with Raynaud’s does not automatically mean heart disease. It can come from esophageal spasm, musculoskeletal causes, or anxiety. But the high prevalence in studies has pushed researchers to look more carefully at whether the coronary arteries themselves are involved.

Myocardial Raynaud’s in Systemic Sclerosis

The strongest evidence for heart involvement comes from systemic sclerosis, an autoimmune disease in which Raynaud’s is almost universal. Autopsy studies dating back to the 1970s found a distinctive pattern of damage in the heart muscle of systemic sclerosis patients: patches of tissue death and scarring scattered throughout both ventricles, even though the large coronary arteries were wide open. The type of damage, called contraction band necrosis, looked like what you would expect from repeated episodes of blood-vessel spasm and then reopening. Researchers described it as “intramyocardial Raynaud’s phenomenon,” the same spasm-relax cycle that happens in fingers, happening inside the heart wall.²

This is not a minor finding. Progressive scarring of the heart muscle leads to stiffness, and stiffness leads to diastolic dysfunction, meaning the heart has trouble relaxing and filling with blood between beats. Echocardiography studies have found that about one in five systemic sclerosis patients has diastolic dysfunction of the left ventricle, even after accounting for other causes like pulmonary hypertension. That diastolic dysfunction is independently associated with higher mortality.³ Over time, the fibrosis can progress to a restrictive pattern where the heart simply cannot pump enough blood to meet the body’s needs.

Coronary Vasospasm Can Mimic a Heart Attack

Beyond the slow accumulation of scar tissue, Raynaud’s-related vasospasm in the coronary arteries can cause acute events. A documented case involved a patient with Raynaud’s who developed severe shortness of breath. Invasive testing with a drug that provokes coronary spasm (ergonovine) revealed that the coronary arteries were clamping down, causing the heart to stiffen temporarily and lose its ability to relax properly between beats.⁴ The symptoms resolved when the spasm stopped, confirming that the problem was transient vasospasm rather than a permanent blockage.

This kind of episode can look a lot like a heart attack on an EKG or by symptoms, but the mechanism is completely different. There is no fatty plaque rupturing. Instead, the artery’s smooth muscle squeezes shut, starving a patch of heart muscle of blood for a brief period. If it happens often enough, though, the repeated injury adds up to permanent damage, which is why researchers believe repeated coronary vasospasm is the driving force behind the fibrosis pattern seen at autopsy in systemic sclerosis patients.

Why the Heart Is Vulnerable to the Same Process

The blood vessels in your fingers and toes are not biologically unique. They share the same endothelial lining and smooth muscle architecture as blood vessels elsewhere, including inside the heart. Several overlapping mechanisms explain why Raynaud’s can be more than skin deep.

People with Raynaud’s tend to have lower levels of nitric oxide, a molecule that tells blood vessels to relax.⁵ When nitric oxide is scarce, vessels are more prone to clamping shut, and that applies to coronary vessels just as it does to digital ones. In systemic sclerosis specifically, both the endothelium-dependent and endothelium-independent pathways of blood-vessel relaxation are impaired, and the vessel walls themselves are thicker than normal.⁶ This combination means the vessels are both harder to open and quicker to snap shut.

Another piece of the puzzle involves the receptors that respond to adrenaline-like signals. People with vasospastic Raynaud’s tend to have elevated levels of a specific receptor type on their platelets, which may represent a fundamental abnormality in how their blood vessels respond to stress signals.⁷ If those same receptors are overexpressed in coronary vessel walls, the heart’s small arteries could be unusually sensitive to cold or emotional stress.

Changes in the Heart’s Own Nerve Supply

The heart does not rely solely on blood supply to function. It also has its own nerve network, and that network appears to behave differently in people with primary Raynaud’s. A study using heart imaging with a radioactive tracer that tracks sympathetic nerve activity found that patients with primary Raynaud’s had significantly lower uptake of the tracer in the heart compared to healthy controls. This was true in both early and late imaging windows.⁸

What does lower sympathetic uptake in the heart mean practically? It suggests the autonomic nervous system, the part you cannot consciously control, is wired differently in Raynaud’s patients. Whether this translates to a higher risk of rhythm disturbances or other cardiac problems is not yet clear, but it reinforces the idea that Raynaud’s is a systemic condition, not just a quirk of the fingertips.

Primary Versus Secondary Raynaud’s and Cardiac Risk

Distinguishing primary Raynaud’s (no underlying disease) from secondary Raynaud’s (tied to conditions like systemic sclerosis, lupus, or mixed connective tissue disease) matters for the heart. One study comparing the two groups found that traditional cardiovascular risk markers like homocysteine, C-reactive protein, and cholesterol were similar between primary and secondary Raynaud’s patients, and there was no difference in the prevalence of standard cardiovascular risk factors.⁹ In other words, the traditional risk-factor profile does not explain any excess cardiac risk.

Cardiac MRI studies help draw a clearer line. When researchers used advanced imaging to look at heart-muscle scarring, they found small areas of damage in some patients with secondary Raynaud’s linked to lupus, mixed connective tissue disease, and systemic sclerosis, but in none of the patients with primary Raynaud’s.¹⁰ A separate MRI study of systemic sclerosis patients found that a marker of diffuse fibrosis in the heart muscle was higher in patients than in controls, and higher values predicted more cardiac events over time.¹¹

Cold-stress cardiac MRI adds another dimension. When systemic sclerosis patients were exposed to a cold stimulus while having their heart imaged, the increase in heart-muscle blood flow was significantly blunted compared to healthy controls, even in patients who had no cardiac symptoms.¹² The heart was failing to open its tiny blood vessels in response to cold the same way the fingers fail to, but the patients did not feel it. This silent microvascular dysfunction is one reason cardiac screening matters in systemic sclerosis.

Long-Term Cardiovascular Mortality

The most provocative population-level finding comes from a long-running cohort study that followed participants for more than twenty years. After that length of follow-up, the presence of Raynaud’s was associated with about a 60 percent increase in the risk of dying from cardiovascular disease among white participants, though the association was not found among Black participants in the same cohort.¹³

This is a single cohort study, so the numbers should be taken as hypothesis-generating rather than definitive. The racial difference is unexplained and complicates interpretation. But it does raise the possibility that even garden-variety Raynaud’s, with no autoimmune disease attached, could be a marker for something going on in the cardiovascular system that matters over decades. Whether Raynaud’s is a direct cause of cardiovascular death or just a signal of underlying vascular vulnerability remains an open question.

Why Raynaud’s Affects Women More and What Estrogen Has to Do with It

Raynaud’s is far more common in premenopausal women than in men of the same age, and the hormone estrogen appears to be a major reason why. Estrogen directly increases the production of a specific cold-sensitive receptor on the smooth muscle cells of skin arteries. In lab experiments, exposing arterial smooth muscle to estrogen ramped up both the expression and the activity of this receptor, and in mouse tail arteries, estrogen selectively amplified the constriction triggered by cold.¹⁴ A comprehensive review confirmed this link, noting that estrogen potentiates the receptor that is the primary mediator of cold-triggered constriction in the skin.¹⁵

The cardiac angle is interesting here because estrogen also has well-known effects on blood vessels in the heart, generally considered protective against atherosclerosis. In systemic sclerosis patients, short-term estrogen administration actually improved the impaired endothelial function that contributes to vasospasm.⁶ So estrogen seems to push in two opposing directions at once: it makes the peripheral cold-sensitive receptors more active (worsening Raynaud’s attacks in the fingers), but it can also relax endothelial dysfunction deeper in the body. How these competing effects play out in the coronary circulation over a lifetime is not well understood.

Nailfold Capillaroscopy as a Window into the Heart

One of the more intriguing ideas in this field is that looking at the tiny blood vessels visible under the fingernail can give you information about what is happening in the heart. Nailfold capillaroscopy, a simple microscope examination of the capillaries at the base of the fingernail, is already standard for distinguishing primary from secondary Raynaud’s. Researchers have proposed that the severity of capillary damage seen at the nailfold could predict microvascular involvement in the heart, since the same disease process attacking the smallest vessels in the fingers is presumably attacking the smallest vessels elsewhere.¹⁶

This is still more of a concept than a validated clinical tool for cardiac screening. But the logic is appealing: if the capillaries you can see without any invasive procedure look damaged, the capillaries you cannot see inside the heart may be damaged too. For patients with systemic sclerosis who need regular monitoring, the nailfold findings could eventually help prioritize who gets cardiac MRI or echocardiography.

Treatments That Help Both the Fingers and the Heart

A practical upside of the Raynaud’s-heart connection is that several treatments overlap. Calcium-channel blockers, the first-line drug class for Raynaud’s attacks, are also widely used for high blood pressure, angina, and coronary vasospasm.¹⁷ They work by relaxing smooth muscle in blood-vessel walls, which is exactly the mechanism you want whether the problematic spasm is happening in a finger or a coronary artery.

For patients who do not respond adequately to calcium-channel blockers, sildenafil has shown benefit. In a crossover trial of patients with treatment-resistant Raynaud’s, sildenafil cut the frequency of attacks by about a third, shortened their total duration by nearly half, and more than quadrupled capillary blood flow velocity.¹⁷ A dose-ranging study found that the higher dose was needed to significantly counteract cold-induced blood-flow drops, while the lower dose fell short.¹⁸ Sildenafil works by boosting nitric oxide signaling, the very pathway that is suppressed in Raynaud’s, and its cardiovascular effects are well established from its original development as a heart drug.

Non-drug approaches also have evidence behind them. Temperature biofeedback training, where patients learn to voluntarily warm their hands using guided physiological feedback, has achieved reductions in reported symptom frequency ranging from about two-thirds to over 90 percent in controlled studies of primary Raynaud’s.¹⁹ Whether biofeedback has any effect on the coronary microcirculation has not been studied, but improving autonomic control of blood-vessel tone is at least theoretically relevant body-wide.

When to Worry and When Not To

If you have primary Raynaud’s with no autoimmune disease, the risk of serious heart involvement is low. The finger-color changes are annoying and sometimes painful, but the imaging evidence consistently shows that primary Raynaud’s patients do not develop the heart-muscle scarring seen in autoimmune-related cases. The long-term mortality association found in the Charleston cohort study is real but modest, and it is not clear whether it reflects a direct cardiac effect or simply that vascular reactivity is a marker for broader cardiovascular vulnerability.

If your Raynaud’s is secondary to systemic sclerosis or another connective tissue disease, cardiac involvement deserves active monitoring. Silent diastolic dysfunction, subclinical fibrosis detectable on MRI, and blunted coronary blood-flow responses to cold are all documented in patients who feel fine. Screening with echocardiography is standard in systemic sclerosis management, and cardiac MRI is increasingly used when echocardiographic findings are borderline or when the clinical picture does not add up.

For anyone with Raynaud’s who experiences unexplained chest tightness, shortness of breath on exertion, or episodes of feeling faint during cold exposure, it is worth mentioning Raynaud’s to a cardiologist. The reflex for most doctors hearing “chest pain” is to think about blocked arteries, but coronary vasospasm requires different diagnostic tools and different treatment strategies. An ergonovine provocation test or cold-stress cardiac imaging can reveal spasm that a standard stress test would miss entirely.